Surgical Innovations

Nonsensical Processes Prevent Patient Access to New and Safe Treatments

Health technological innovations only have value if doctors and patients have access to them. Insurance companies label new products as investigational to justify the denial of care. Nonsensical processes prevent patient access to new, safe, and effective treatments.

The pandemic proved new therapeutics and vaccines are able to navigate through the bureaucratic quagmire when there is the public will to make it happen. New antivirals therapies, monoclonal antibodies, and mRNA vaccines are now saving lives. 

These success stories are outliers. In reality, pharmaceutical and medical device innovations move through the system at a snail’s pace. 

A product must pass through a lengthy FDA approval process to verify safety and efficacy. Despite FDA approval, a new medical device still can not get into the hands of surgeons. New technologies run into a brick wall as they fight for acceptance as an approved product by third-party payers. 

Insurance companies hide behind the word “investigational” to justify the denial of care. An FDA-approved medical device has little value to doctors and patients if none of the third-party payers pay for its use. 

Every insurance company must accept and authorize a new medication or medical device into their approved formulary before it is considered a covered benefit. Even after CMS approval, each managed care Medicare and Medicaid plan also submit new products to this lengthy process.

Medical practices spend countless hours jumping through pre-authorization hoops and appealing denied claims. 

We invest this time and energy to get our patients the most effective options, but patient care does not have to be so hard. Patients want doctors to spend time in the exam room, not writing insurance appeal letters. 

Finn Partners manager of global health, Gil Bashe, summarizes the barriers stifling medical device innovation in his article “Investigational” Is Payer Code for “Coverage Denied”

It is time for insurance companies to tear down the walls, stop playing games and help doctors provide the best care to their patients. 

Dr Jeff Livingston

Jeff is Co-Founder of Medika Life. He is a Board Certified Obgyn and CEO of MacArthur Medical Center in Irving, Texas. He is a nationally recognized thought leader, speaker, writer, blogger, and practicing physician who is considered an expert in the use of social media to educate patients, using new and innovative technology to improve care outcomes and the patient experience.

Recent Posts

The Invisible Lifeline: Why Supplies, Not Just Science, Determine Patient Care

In the health system, news coverage naturally gravitates toward breakthroughs. A new therapy, a diagnostic…

6 days ago

Nature as Infrastructure: Why the Urban Tree Is an Investable Asset

I first learned about the urban heat island effect in a high school geography class.…

1 week ago

From AI Excitement to Execution: Why Health Leaders Must Now Master the “How”

Artificial intelligence is advancing in health care faster than almost any other technology in modern…

3 weeks ago

The Shift from Pure Modernity to Human-Centered Modernity

Throughout the history of science, it has rarely been the case that any phenomenon has…

3 weeks ago

We Have to Earn Better Vaccine Coverage Rates

Mandates and strong recommendations have been the key to successful vaccination programmes protecting people for…

3 weeks ago

Brain Organoids: Promise, Limits, and What Comes Next

Brain organoids, sometimes called “mini-brains,” are three-dimensional clusters of human brain cells grown in labs from pluripotent stem…

3 weeks ago

This website uses cookies. Your continued use of the site is subject to the acceptance of these cookies. Please refer to our Privacy Policy for more information.

Read More